What is Vfend drug? how to take medicine

Drug information Vfend 200mg Voriconazole treats fungal infections

Trade name: Vfend
Active ingredient: Voriconazole.
Content: 200mg.
Packaging: Box of 30 tablets.
Manufacturer: Pfizer.
Vfend drug quote: Contact directly or leave a comment here

What is Vfend 200mg Voriconazole?

Vfend 200mg contains the active ingredient Voriconazole which is an antifungal medicine. Vfend is a prescription medicine used to treat infections caused by yeast or other fungi. Infections such as: aspergillosis, esophageal candidiasis, Scedosporium, Fusarium and candidemia.

It is not known whether Vfend is safe and effective in children younger than 2 years of age.

The mechanism of action of the active ingredient Voriconazole

Active ingredient Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is to inhibit fungal cytochrome P450-mediated demethylation of 14 alpha-lanosterol, an essential step in fungal ergosterol biosynthesis.

Accumulation of 14 alpha-methyl sterols correlates with subsequent loss of ergosterol in fungal cell membranes and may be responsible for the antifungal activity of voriconazole. The active substance has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.

Indications for treatment of Vfend

Vfend is a broad-spectrum antifungal drug of the Azol group, indicated for the prevention and treatment of fungal infections in adults and children over 2 years of age in the following cases:

Aspergillus infections, including: Aspergillus infections of the lungs, bronchial branches, bone marrow and organs.
Candidemia in patients without leukopenia.
Invasive Candida infections: C.tropicalis, C.glabrata, C.kruisei… including cases resistant to fluconazole and intraconazole.
Severe fungal infections caused by Scedosporium spp. and Fusarium spp.
Esophageal candidiasis
Acute, life-threatening fungal infections, including filamentous fungi and yeasts.
Prophylactic treatment of fungal infections in high-risk subjects: Patients with bone marrow transplantation, patients with leukemia relapse.

Contraindications to the use of Vfend

Hypersensitivity to the active substance Voriconazole or any of the ingredients in Vfend .
Patients with severe liver failure.
Co-administration with CYP3A4 substrates, terfenadine, astemizol, cisapride, pimozide or quinidine because increased plasma concentrations of the medicinal products may lead to QT prolongation and the rare occurrence of torsades de pointes .

Dosage of Vfend

The recommended starting dose is: 200mg or 400mg taken 12 hours apart for the first 24 hours.
After the first 24 hours the recommended dose is: 100 mg or 200 mg, orally twice daily.

For both the starting dose and the maintenance dose, the dose used depends on your body weight and the type of infection.

Prophylactic dose in subjects at high risk of fungal infections: use Vfend 200 at a dose of 9mg/kg x 2 times/day, but not exceed 350mg x 2 times/day.

Prophylactic treatment should be started on the day of leave and can be maintained for up to 100 days. Prophylactic treatment should be as short as possible depending on the risk of developing an invasive fungal infection (IFI) with neutrophil status or immunodeficiency. Prophylactic doses only last up to 180 days from transplantation in cases of continued immunosuppression or GVHD.

Dose adjustment